Evidence map›Paper›PMID 40296625›Full record

ReviewCNS & neurological disorders drug targets2025

Cell-Free DNA, a Noninvasive Biomarker for Prediction and Detection of Neurodegenerative Diseases, New Insights, and Perspectives.

Tahere Barabadi, Elahe Sadat Mirjalili, Seyed Mahdi Mohamadi-Zarch, Hossein Rahimi, Fariborz Keshmirshekan, Seyyed Majid Bagheri

Abstract readReview
PubMed Publisher
In one paragraph

Review in CNS & neurological disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tahere BarabadiCellular and Molecular Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Elahe Sadat MirjaliliFaculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyed Mahdi Mohamadi-ZarchDepartment of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yard, Iran.
Hossein RahimiFaculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Fariborz KeshmirshekanFaculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyyed Majid BagheriDepartment of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yard, Iran.

Funding

Shahid Sadoughi University of Medical Science and Health Services 18535
6 · The paper itself

Abstract

Neurodegenerative diseases pose serious threats to public health worldwide. Biomarkers for neurodegenerative disorders are essential to enhance the diagnostic process in clinical settings and to aid in the creation and assessment of effective disease-modifying treatments. In recent times, affordable and readily available blood-based biomarkers identifying the same neurodegenerative disease pathologies have been created, potentially transforming the diagnostic approach for these disorders worldwide. Emerging relevant biomarkers for α-synuclein pathology in Parkinson's disease include blood-based indicators of overall neurodegeneration and glial activation. Cell-free DNA (cfDNA), an encouraging non-invasive biomarker commonly utilized in oncology and pregnancy, has demonstrated significant potential in clinical uses for diagnosing neurodegenerative disorders. In this section, we explore the latest cfDNA studies related to neurodegenerative disorders. Moreover, we present a perspective on the possible role of cfDNA as a diagnostic, therapeutic, and prognostic indicator for neurodegenerative disorders. This review provides a summary of the most recent progress in biomarkers for neurodegenerative disorders such as Alzheimer's, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and traumatic brain injury.

Indexed as

Cell-Free Nucleic AcidsNeurodegenerative DiseasesAnimalsBiomarkersHumansParkinson DiseaseBiomarkersCell-Free Nucleic AcidsAlzheimer'samyotrophic lateral sclerosisCell-free DNAmultiple sclerosisParkinson's diseasetraumatic brain injury.

Identifiers

PMID40296625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.